Efrat Dotan, MD

Hematology, Medical Oncology
Accepting new patients
Sees patients age 18 and up
LG Health Physicians Hematology and Medical Oncology
Make an appointmentCall 717-544-9400
Headshot of Efrat Dotan, MD
Penn Medicine Provider

About me

  • Executive Medical Director, Ann B. Barshinger Cancer Institute, Penn Medicine Lancaster General Health
  • Executive Medical Director, Cancer Services, Penn Medicine Lancaster General Health
  • Executive Medical Director, Cancer Research, Penn Medicine Lancaster General Health
  • Chairperson, Cancer Committee, Penn Medicine Lancaster General Health
  • Clinical Professor of Medicine (Hematology-Oncology)

I am a medical oncologist specializing in the care of patients with gastrointestinal malignancies. While I treat all GI cancers, my primary clinical and research focus is pancreatic cancer, with an emphasis on improving outcomes through clinical trials of new treatment options. I strongly believe that advances in cancer care are driven by the courage of patients who participate in clinical trials. I lead efforts at our center to expand access to these studies.

In addition, I have a strong interest in the care of older adults with cancer. I work closely with social work, physical therapy, nutrition, caregivers, and our geriatric oncology team to treat this population. I also am actively involved in national groups dedicated to improving cancer care for older adults with the goal to provide care that is not only effective, but also compassionate, personalized, and supportive of quality of life.

 

My education and training

  • Medical School: Technion - Israel Institute of Technology
  • Residency: Lenox Hill Hospital
  • Fellowship: Fox Chase Cancer Center

Reviews

Average Rating

85 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
she is very knowledgeable.
Anonymous
April 2026
dr. dotan was very thorough
Anonymous
April 2026
personable and thorough
Anonymous
April 2026
she knows her stuff

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Lancaster General Hospital: Has privileges to treat patients in the hospital.
Dr. Dotan is a Penn Medicine Lancaster General Health physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Dotan E, Catalano PJ, Lenchik L, Boutin R, Yao X, Ohr J, Lim KH, Vijayvergia N, Chandana SR, Kalyan A, Dunne RF, Zhen DB, Li D, Simon MA, Berlin J, Wagner LI, O'Dwyer PJ. Randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT) , ECOG-ACRIN Annual Meeting, Fort Lauderdale, FL.: 2024

Sedrak MS, Sun CL, Bae M, Freedman RA, Magnuson A, O'Connor T, Moy B, Wildes TM, KlepinHD, Chapman AE, Tew WP, Dotan E, Fenton MA, Kim H, Katheria V, Muss HB, Cohen HJ, Gross CP, Ji J. Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study , J Cancer Surviv , 18(4): 2024,1131-1143.

Persley CJ, Baumgart M, Halmos B, Dotan E. Cancer rarely travels Alone: Addressing the accumulation of risk and early mortality form older adults with advanced lung cancer. , J Geriatr Oncol, 15(6): 2024,101579

Ioffe D, Bhatia-Patel SC, Gandhi S, Hamad EA, Dotan E. Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer: JACC Family Series , JACC CardioOncol , 6(2): 2024,143-158.

Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials Kaur M, Frahm F, Lu Y, Ascha MS, Guadamuz JS, Dotan E, Gottesman A, Leybovich BC, Sondhi A,Zhao Y, Meropol NJ, Royce TJ. , NEJM Evid , 3(4): 2024,EVIDoa2300236.

JiJ, Bae M, Sun CL, Wildes TM, Freedman RA, Magnuson A, O’Connor T, Moy B, Klepin HD, Chapman AE, Tew, WP, Dotan E, Fenton MA, Kim H, Kateria V, Gross CP, Cohen HJ, Muss JB, Sedrak MS. Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial , Cancer , 130(6): 2024,936-946.

Disparities in care of older adults of color with cancer: A narrative review. Dotan E, Lynch SM, Ryan JC, Mitchell EP. , Cancer Med , 13(3): 2024,e6790.

Yankey H, Ruth KJ, Dotan E, Reddy S, Meyer J. Survival and Toxicity in Patients With Unresectable or Inoperable Biliary Tract Cancers With Ablative Radiation Therapy Versus Nonablative Chemoradiation , Adv Radiat Oncol , 9(4): 2023,101412.

Ioffe D. and Dotan E. Evidence-Based Care of Older Adults With Metastatic Colorectal Cancer: Insights From Landmark Clinical Trials , J Clin Oncol, 41(34): 2023,5228-5236.

Fernandez SV, Tan YF, Rao S, Fittipaldi P, Sheriff F, Borghaei H, Dotan E, Winn JS, Edelman MJ, Treat J, Judd J, Alpaugh RK, Wang YL, Yu JQ, Wasik M, Baldwin DA. Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing , Int J Mol Sci , 24(21): 2023,15779.